KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rigel Pharmaceuticals (RIGL) EBT Margin (2016 - 2025)

Rigel Pharmaceuticals has reported EBT Margin over the past 15 years, most recently at 32.54% for Q4 2025.

  • For Q4 2025, EBT Margin rose 611.0% year-over-year to 32.54%; the TTM value through Dec 2025 reached 41.4%, up 3115.0%, while the annual FY2025 figure was 41.4%, 3115.0% up from the prior year.
  • EBT Margin for Q4 2025 was 32.54% at Rigel Pharmaceuticals, down from 39.76% in the prior quarter.
  • Over five years, EBT Margin peaked at 58.99% in Q2 2025 and troughed at 164.0% in Q1 2022.
  • A 5-year average of 21.48% and a median of 11.51% in 2023 define the central range for EBT Margin.
  • On a YoY basis, EBT Margin climbed as much as 11396bps in 2022 and fell as far as -21494bps in 2022.
  • Year by year, EBT Margin stood at 111.23% in 2021, then surged by 102bps to 2.73% in 2022, then dropped by -25bps to 2.06% in 2023, then soared by 1184bps to 26.43% in 2024, then increased by 23bps to 32.54% in 2025.
  • Business Quant data shows EBT Margin for RIGL at 32.54% in Q4 2025, 39.76% in Q3 2025, and 58.99% in Q2 2025.